Development of a salmon-derived crosslinked atelocollagen sponge disc containing osteogenic protein-1 for articular cartilage regeneration: in vivo evaluations with rabbits

BMC Musculoskeletal Disorders

Kazunori Yasuda³  Hirokazu Iida¹  Nobuhiro Nagai²  Nobuto Kitamura³  Yasuyuki Kawaguchi³  Eiji Kondo³  Hiroyuki Mori¹ 

[1] Department of Orthopaedic Surgery, Kansai Medical University, Osaka, Japan;Department of Translational Research, Tohoku University School of Medicine, Sendai, Japan;Department of Sports Medicine and Joint Surgery, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo 060-8638, Japan

关键词: Biomaterial;    Scaffold;    Cartilage Regeneration;    Crosslinked Collagen;    Salmon-derived Atelocollagen Sponge;   

Others  :  1132623
DOI  :  10.1186/1471-2474-14-174

 received in 2012-12-02, accepted in 2013-05-21,  发布年份 2013

【 摘 要 】

Background

We have developed crosslinked salmon-derived atelocollagen sponge, which has a denaturation temperature of 47 degrees Celsius. The purpose of this study is to evaluate the fundamental in vivo efficacy of the osteogenic protein (OP) -1 containing salmon-derived collagen sponge disc (SCS) on cartilage regeneration, using a rabbit model.

Methods

A total of 24 rabbits were used in this study. In each animal, a full-thickness osteochondral defect was created in each femoral trochlea. Then, each 12 rabbits were randomly divided into the two groups. In Group I, an OP1-SCS disc was implanted into the defect in the right knee. In Group II, a SCS disc without OP-1 was implanted into the defect in the right knee. A control group of 12 rabbits was assembled from randomly-selected left knees from among the first two groups. In Group-III, we applied no treatment for a defect in the left knee to obtain the untreated control. All rabbits were sacrificed at 12 weeks after surgery. In each group, 10 animals were used for histological and immunohistological evaluations, and the remaining 2 were used for real-time polymerase chain reaction (PCR) analyses.

Results

In Group I, a regenerated cartilage tissue rich in proteoglycan and type-2 collagen was found at 12 weeks, although the width was thicker than that of Group II. In Group II, the defect was filled with thick inhomogeneous tissues, including cartilage, fibrous, and bone tissues at 12 weeks. Concerning the gross observation and histological scores at 12 weeks, the ANOVA showed significant differences (p < 0.0001, and p < 0.0001, respectively). The post-hoc test indicated that the gross observation and histological scores of Group I was significantly greater than those of Groups II (p = 0.035, and p = 0.0104, respectively) and III (p < 0.0001, and p < 0.0001, respectively), while Group II was significantly greater than Group III (p = 0.0069, and p = 0.005, respectively). The real time PCR analysis showed that gene expression of type-2 collagen and aggrecan of Group I was greater than that of Group II.

Conclusions

The present study clearly demonstrated that the implantation of the OP1-SCS disc without any cultured cells may induce spontaneous hyaline-like cartilage regeneration to greater degrees than implantation of only the salmon-derived collagen sponge disc.

【 授权许可】

   
2013 Mori et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 1.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Brittberg M, Lindahl A, Nilsson A, Ohlsson C, Isaksson O, Peterson L: Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. New Engl J Med 1994, 331:889-895.
• [2]Peterson L, Minas T, Brittberg M, Lindahl A: Treatment of osteochondritis dissecans of the knee with autologous chondrocyte transplantation: results at two to ten years. J Bone Joint Surg Am 2003, 85:17-24.
• [3]Ochi M, Adachi N, Nobuto H, Yanada S, Ito Y, Agung M: Articular cartilage repair using tissue engineering technique–novel approach with minimally invasive procedure. Artif Organs 2004, 28:28-32.
• [4]Knutsen G, Drogset JO, Engebretsen L, Grøntvedt T, Isaksen V, Ludvigsen TC, Roberts S, Solheim E, Strand T, Johansen O: A randomized trial comparing autologous chondrocyte implantation with microfracture. Findings at five years. J Bone Joint Surg Am 2007, 89:2105-2112.
• [5]Swatschek D, Schatton W, Kellermann J, Müller WE, Kreuter J: Marine sponge collagen: isolation, characterization and effects on the skin parameters surface-pH, moisture and sebum. Eur J Pharm Biopharm 2002, 53:107-113.
• [6]Yunoki S, Suzuki T, Takai M: Stabilization of low denaturation temperature collagen from fish by physical cross-linking methods. J Biosci Bioeng 2003, 96:575-577.
• [7]Burjanadze TV: Thermodynamic substantiation of water-bridged collagen structure. Biopolymers 1992, 32:941-949.
• [8]Nagai N, Yunoki S, Suzuki T, Sakata M, Tajima K, Munekata M: Application of crosslinked salmon atelocollagen to the scaffold of human periodontal ligament cells. J Biosci Bioeng 2004, 97:389-394.
• [9]Yunoki S, Nagai N, Suzuki T, Munekata M: Novel biomaterial from reinforced salmon collagen gel prepared by fibril formation and cross-linking. J Biosci Bioeng 2004, 98:40-47.
• [10]Nagai N, Mori K, Saoh Y, Takahashi N, Yunoki S, Tajima K, Munekata M: In vitro growth and differentiated activities of human periodontal ligament fibroblasts cultured on salmon collagen gel. J Biomed Mater Res A 2007, 82:395-402.
• [11]Nagai N, Mori K, Munekata M: Biological properties of crosslinked salmon collagen fibrillar gel as a scaffold for human umbilical vein endothelial cells. J Biomater Appl 2008, 23:275-287.
• [12]Kawaguchi Y, Kondo E, Kitamura N, Arakaki K, Tanaka Y, Munekata M, Nagai N, Yasuda K: In vivo effects of isolated implantation of salmon-derived crosslinked atelocollagen sponge into an osteochondral defect. J Mater Sci Mater Med 2011, 22:397-404.
• [13]Sakou T: Bone morphogenetic proteins: from basic studies to clinical approaches. Bone 1998, 22:591-603.
• [14]Loeser RF, Pacione CA, Chubinskaya S: The combination of insulin-like growth factor-1 and osteogenic protein-1 promotes increased survival of and matrix synthesis by normal and osteoarthritic human articular chondrocytes. Arthritis Rheum 2003, 48:2188-2196.
• [15]Chubinskaya S, Merrihew C, Cs-Szabo G, Mollenhauer J, McCartney J, Rueger DL, Kuettner KE: Human articular chondrocytes express osteogenic protein-1. J Histochem Cytochem 2000, 48:239-250.
• [16]Chubinskaya S, Hakimiyan A, Pacione C, Yanke A, Rappoport L, Aigner T, Rueger D, Loeser RF: Synergistic effect of IGF-1 and OP-1 on matrix formation by normal and OA chondrocytes cultured in alginate beads. Osteoarthritis Cartilage 2007, 15:421-430.
• [17]Chubinskaya S, Kawakami M, Rappoport L, Matsumoto T, Migita N, Rueger DC: Anti-catabolic effect of OP-1 in chronically compressed intervertebral discs. J Ortho Res 2007, 25:517-530.
• [18]Hayashi R, Kondo E, Tohyama H, Saito T, Yasuda K: In vivo local administration of osteogenic protein-1 increases structural properties of the overstretched anterior cruciate ligament with partial midsubstance laceration. A biomechanical study in rabbits. J Bone Joint Surg Br 2008, 90:1392-1400.
• [19]Wayne JS, McDowell CL, Shields KJ, Tuan RS: In vivo response of polylactic acid-alginate scaffolds and bone marrow-derived cells for cartilage tissue engineering. Tissue Eng 2005, 11:953-963.
• [20]Nishikawa A, Taira T, Yoshizato K: In vitro maturation of collagen fibrils modulates spreading, DNA synthesis, and collagenolysis of epidermal cells and fibroblasts. Exp Cell Res 1987, 171:164-177.
• [21]Kuzuya M, Satake S, Ai S, Asai T, Kanda S, Ramos MA, Miura H, Ueda M, Iguchi A: Inhibition of angiogenesis on glycated collagen lattices. Diabetologia 1998, 41:491-499.
• [22]Semler EJ, Ranucci CS, Moghe PV: Mechanochemical manipulation of hepatocyte aggregation can selectively induce or repress liver-specific function. Biotechnol Bioeng 2000, 69:359-369.
• [23]Flechtenmacher J, Huch K, Thonar EJ-MA, Mollenhauer JA, Davies SR, Schmid TM, Puhl W, Sampath TK, Aydelotte MB, Kuettner KE: Recombinant human osteogenic protein 1 is a potent stimulator of the synthesis of cartilage proteoglycans and collagens by human articular chondrocytes. Arthritis Rheum 1996, 39:1896-1904.
• [24]Lietman S, Yanagishita M, Sampath TK, Reddi AH: Stimulation of proteoglycan synthesis in explants of porcine articular cartilage by recombinant osteogenic protein-1 (bone morphogenetic protein-7). J Bone Joint Surg Am 1997, 79:1132-1137.
• [25]Nishida Y, Knudson CB, Eger W, Kuettner KE, Knudson W: Osteogenic protein-1 stimulates cell-associated matrix assembly by normal human articular chondrocytes: upregulation of hyaluronan synthase, CD 44 and aggrecan. Arthritis Rheum 2000, 43:206-214.
• [26]Chubinskaya S, Kumar B, Merrihew C, Heretis K, Rueger D, Kuettner KE: Age-related changes in cartilage endogenous OP-1. Biochimica Biophysica Acta Mol Basis Dis 2002, 1588:126-134.
• [27]Fan Z, Chubinskaya S, Rueger DC, Bau B, Haag J, Aigner T: Regulation of anabolic and catabolic gene expression in normal and osteoarthritic adult human articular chondrocytes by OP-1 (BMP-7). J Clin Exper Rheum 2004, 22:103-106.
• [28]Loeser R, Chubinskaya S, Pacione C, Im H-J: Basic fibroblast growth factor inhibits the anabolic activity of insulinlike growth factor-1 and osteogenic protein-1 in adult human articular chondrocytes. Arthritis Rheum 2005, 52:3910-3917.
• [29]Huch K, Wilbrink B, Flechtenmacher J, Koepp HE, Aydelotte MB, Sampath TK, Kuettner KE, Mollenhauer JA, Thonar EJMA: Effects of recombinant human osteogenic protein 1 on the production of proteoglycan, prostaglandin E2, and interleukin-1 receptor antagonist by human articular chondrocytes cultured in the presence of interleukin-1beta. Arthritis Rheum 1997, 40:2157-2161.
• [30]Koepp HE, Sampath KT, Kuettner KE, Homandberg GA: Osteogenic protein-1 (OP-1) blocks cartilage damage caused by fibronectin fragments and promotes repair by enhancing proteoglycan synthesis. Inflamm Res 1999, 47:1-6.
• [31]Im HJ, Pacione C, Chubinskaya S, VanWijnen AJ, Sun Y, Loeser RF: Inhibitory effects of insulin-like growth factor-1 and osteogenic protein-1 on fibronectin fragment- and interleukin-1beta-stimulated matrix metalloproteinase-13 expression in human chondrocytes. J Biol Chem 2003, 278:25386-25394.
• [32]Louwerse RT, Iheyligers IC, Klein-Nulend J, Sugiihara S, van Kampen GPJ, Semeins CM, Goei SW, de Koning MHMT, Wuisman PIJM, Burger EH: Use of recombinant human osteogenic protein-1 for the repair of subchondral defects in articular cartilage in goats. J Biomed Mater Res 2000, 49:506-516.
• [33]Jelic M, Pecina M, Haspl M, Kos J, Taylor K, Maticic D, McCartney J, Yin S, Rueger D, Vukicevic S: Regeneration of articular cartilage chondral defects by osteogenic protein-1 (bone morphogenetic protein-7) in sheep. Growth Fact 2001, 19:101-113.
• [34]Cook SD: Preclinical and clinical evaluation of osteogenic protein-1 (BMP-7) in bony sites. Orthopedics 1999, 22:669-671.
• [35]Hayashi M, Muneta T, Ju YJ, Mochizuki T, Sekiya I: Weekly intra-articular injections of bone morphogenetic protein-7 inhibits osteoarthritis progression. Arthritis Res Ther 2008, 10(5):R118. BioMed Central Full Text
• [36]Friedlaender GE, Perry CR, Cole JD, Cook SD, Cierny G, Muschler GF, Zych GA, Calhoun JH, LaForte AJ, Yin S: Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 2001, 83:151-158.
• [37]Kanayama M, Hashimoto T, Shigenobu K, Yamane S, Bauer TW, Togawa D: A prospective randomized study of posterolateral lumbar fusion using osteogenic protein-1 (OP-1) versus local autograft with ceramic bone substitute: emphasis of surgical exploration and histologic assessment. Spine 2006, 31:1067-1074.